ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundNeuroactive ligand-receptor interaction may influence the development of gastric cancer. However, the underlying mechanisms have not been elucidated.
methodsBased on single-cell, spatial transcriptome, bulk transcriptome data and immunofluorescence in gastric cancer, we validated cells associated with neuroactive ligand-receptor interaction pathways, prognostic genes and communication signaling direction at spatial level.
resultsNeuroactive ligand-receptor interaction gene set was closely related to monocyte-macrophages (Mono-Macs), which with high expression of neuroactive ligand-receptor interaction gene set (NEUROhighMono) had significant communication interactions with immune and endothelial cells. Prognostic modeling indicated that patients with high pathway activity had poorer outcomes, characterized by higher stromal scores and elevated immune checkpoint levels. Among related genes, CHRNE was identified as a key marker of poor prognosis, predominantly expressed in Mono-Macs. Integrated spatial transcriptome and immunofluorescence further demonstrated that CHRNE-positive Mono-Macs (CHRNE + Mono) may promote tumor angiogenesis through VEGFA, linking CHRNE to tumor progression and unfavorable prognosis.
conclusionsThis study explored neuroactive ligand-receptor interactions in gastric cancer, revealing that Mono-Macs were significantly influenced by related genes. CHRNE + Mono may regulate tumor microenvironment by promoting angiogenesis, highlighting CHRNE as a potential driver of tumor progression. These findings suggest that neuroactive ligand-receptor interactions, particularly CHRNE, could offer potential therapeutic strategies for gastric cancer.
Indexed as
Identifiers
41239058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.